Literature DB >> 22722502

Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders: results from a 12-month, real-world study.

Jian-Ping Zhang1, Jeffrey J Weiss, Melissa McCardle, Hope Klopchin, Eileen Rosendahl, Lawrence Maayan, Antonio Convit, John M Kane, Peter Manu, Christoph U Correll.   

Abstract

OBJECTIVE: Studies of behavioral weight loss intervention in patients with psychotic disorders are sparse, and its efficacy compared to other obese patients is unknown. Therefore, we compared the effect of a cognitive-behavioral weight loss intervention in obese subjects with psychotic disorders, other psychiatric diagnoses, and without psychiatric disorders.
METHODS: A 12-month naturalistic study of weekly group or individual cognitive-behavioral weight management in 222 consecutively enrolled obese patients (body mass index [BMI], 43.7 ± 9.6 kg/m2) with psychotic spectrum disorders (PSDs, n = 47), other psychiatric disorders (OPDs, n = 49), and no psychiatric disorder (NPD, n = 126).
RESULTS: Patients with PSD had greater treatment persistence (48.9%) and longer treatment duration (8.7 ± 4.4 months) than those with OPD (22.4% and 5.4 ± 4.3 months) and NPD (22.2% and 4.9 ± 4.7 months) (P < 0.01 for all; number needed to treat, 3). In last-observation-carried-forward analyses, patients with PSD had greater percent baseline weight loss at 12 months (5.1% ± 9.3%) than patients with OPD and with NPD (2.7% ± 5.5% and 2.4% ± 6.3%); greater percent BMI loss at 9 and 12 months than both groups (P < 0.05 for all) and greater BMI loss at 9 months (2.1 ± 3.5 kg/m2) and 12 months (2.3 ± 4.1 kg/m2) than NPD patients (1.1 ± 2.3 and 1.2 ± 2.4 kg/m2). Furthermore, weight loss of 5% or more occurred in 42.6% of patients with PSD versus 18.4% and 23.0% in OPD and NPD patients (P < 0.01 for all; numbers needed to treat, 5 and 6). The strongest weight loss predictor was treatment duration (β = 0.51-0.54; P < 0.001). Attrition was predicted by NPD (P = 0.001) and OPD group status (P = 0.036), lower proportion of group sessions (P = 0.002), higher depression (P = 0.028), and lower baseline BMI (P = 0.030).
CONCLUSIONS: Patients with PSD had greater weight loss than other obese patients. Nonadherence and depression should be targeted to enhance weight loss success.

Entities:  

Mesh:

Year:  2012        PMID: 22722502      PMCID: PMC3389573          DOI: 10.1097/JCP.0b013e31825cccd2

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  29 in total

Review 1.  Antipsychotic drugs and obesity.

Authors:  Christoph U Correll; Todd Lencz; Anil K Malhotra
Journal:  Trends Mol Med       Date:  2010-12-22       Impact factor: 11.951

Review 2.  Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis.

Authors:  Lawrence Maayan; Julia Vakhrusheva; Christoph U Correll
Journal:  Neuropsychopharmacology       Date:  2010-03-24       Impact factor: 7.853

3.  The Satisfaction With Life Scale.

Authors:  E Diener; R A Emmons; R J Larsen; S Griffin
Journal:  J Pers Assess       Date:  1985-02

Review 4.  Balancing efficacy and safety in treatment with antipsychotics.

Authors:  Christoph U Correll
Journal:  CNS Spectr       Date:  2007-10       Impact factor: 3.790

Review 5.  A meta-analysis of psycho-behavioral obesity interventions among US multiethnic and minority adults.

Authors:  Dong-Chul Seo; Jaesin Sa
Journal:  Prev Med       Date:  2008-01-16       Impact factor: 4.018

Review 6.  A review of psychosocial pre-treatment predictors of weight control.

Authors:  P J Teixeira; S B Going; L B Sardinha; T G Lohman
Journal:  Obes Rev       Date:  2005-02       Impact factor: 9.213

7.  Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: A randomized controlled trial.

Authors:  Mario Alvarez-Jiménez; Cesar González-Blanch; Jose Luis Vázquez-Barquero; Rocío Pérez-Iglesias; Obdulia Martínez-García; Teresa Pérez-Pardal; Mari Luz Ramírez-Bonilla; Benedicto Crespo-Facorro
Journal:  J Clin Psychiatry       Date:  2006-08       Impact factor: 4.384

8.  Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials.

Authors:  Christoph U Correll; Eva M Sheridan; Melissa P DelBello
Journal:  Bipolar Disord       Date:  2010-03       Impact factor: 6.744

9.  Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.

Authors:  Jaspreet S Brar; Rohan Ganguli; Gahan Pandina; Ibrahim Turkoz; Sally Berry; Ramy Mahmoud
Journal:  J Clin Psychiatry       Date:  2005-02       Impact factor: 4.384

10.  Evaluation of an intensive weight control program using a priori criteria to determine outcome.

Authors:  D Beliard; D S Kirschenbaum; M L Fitzgibbon
Journal:  Int J Obes Relat Metab Disord       Date:  1992-07
View more
  4 in total

1.  Behavioral Weight Loss Treatment in Antipsychotic Treated Youth.

Authors:  Ginger E Nicol; Rachel P Kolko; Monica Mills; Thrudur Gunnarsdottir; Michael D Yingling; Julia A Schweiger; Eric J Lenze; John W Newcomer; Denise Wilfley
Journal:  Scand J Child Adolesc Psychiatr Psychol       Date:  2016-05

2.  Getting to More Effective Weight Management in Antipsychotic-Treated Youth: A Survey of Barriers and Preferences.

Authors:  Ginger Nicol; Elizabeth Worsham; Debra Haire-Joshu; Alexis Duncan; Julia Schweiger; Michael Yingling; Eric Lenze
Journal:  Child Obes       Date:  2016-01-20       Impact factor: 2.992

Review 3.  Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review.

Authors:  Emma E McGinty; Julia Baller; Susan T Azrin; Denise Juliano-Bult; Gail L Daumit
Journal:  Schizophr Bull       Date:  2015-07-28       Impact factor: 9.306

Review 4.  Pharmacogenetics of antipsychotics: recent progress and methodological issues.

Authors:  Jian-Ping Zhang; Anil K Malhotra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-12-01       Impact factor: 4.481

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.